


- **H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 – Rep. David Cicilline**
 - This Act would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring gaming of safety protocols that brand manufacturers use to delay or impede generic entry.
- **H.R. 938: Bringing Low-Cost Options and Competition While Keeping Incentives for New Generics (BLOCKING) Act of 2019 – Rep. Kurt Schrader**
 - This bipartisan legislation would increase competition in the generic drug market by preventing limitless delays caused when a first generic drug manufacturer parks their exclusivity at the tentative approval stage, blocking the approval of other generics.
- **H.R. 1499: Protecting Consumer Access to Generic Drugs Act of 2019 – Rep. Bobby Rush**
 - This Act would make it illegal for brand-name and generic drug manufacturers to enter into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep a generic equivalent off the market.
- **H.R. 1781: Payment Commission Data Act of 2019 – Rep. Tom O’Halleran**
 - This bipartisan legislation provides the Medicare Payment Advisory Commission (MedPAC) and the Medicaid and CHIP Payment and Access Commission (MACPAC) with access to drug pricing and rebate data in order for these independent, non-partisan commissions to help Congress better understand the true costs of prescription drugs to consumers and taxpayers.
- **H.R. 1520: Purple Book Continuity Act of 2019 – Rep. Anna Eshoo**
 - This Act would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book, specify that the Purple Book should be published electronically on FDA’s website and updated routinely, and direct FDA to consider the types of patents that should be listed in the Purple Book.



- **H.R. 1503: Orange Book Transparency Act – Rep. Robin Kelly**
 - This legislation would help to ensure that the Orange Book is accurate and up-to-date, by requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. Patents found to be invalid through a court decision or a decision by the Patent Trial and Appeal Board would be required to be removed promptly.
- **H.R. 1425: State Health Care Premium Reduction Act – Rep. Angie Craig**
 - The State Health Care Premium Reduction Act would make healthcare more affordable by encouraging states to create their own state-based marketplaces, which would cover the costliest medical claims and lower premiums for people across the country. The program is estimated to reduce premiums by as much as 10 percent.
- **H.R. 584: Incentivizing Medicaid Expansion Act – Rep. Marc Veasey**
 - This bill would allow states that have not previously expanded Medicaid coverage under the ACA to be eligible for the same federal matches as those who acted within the window. Under the Affordable Care Act, the federal government covered the full cost of Medicaid expansion during the first three years of the ACA for states that chose to expand their Medicaid programs to cover individuals up to 138 percent of the federal poverty level.